These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19035967)

  • 21. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A
    Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL; García-Paredes J; Cruz Santamaria DM; Lana R; Ramírez Fernández E; Rodríguez Asteaga E; Díaz-Rubio M
    Rev Esp Enferm Dig; 2002 May; 94(5):269-79. PubMed ID: 12474335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed?
    Tanaka S; Matsuo K; Sasaki T; Nakano M; Sakai K; Beppu R; Yamashita Y; Maeda K; Aoyagi K
    Hepatogastroenterology; 2010; 57(97):3-7. PubMed ID: 20422862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease.
    Tanaka T; Takahama K; Kimura T; Mizuno T; Nagasaka M; Iwata K; Nakano H; Muramatsu M; Takazoe M
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1143-9. PubMed ID: 16824066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
    Gisbert JP; Panés J
    Am J Gastroenterol; 2009 Mar; 104(3):760-7. PubMed ID: 19174781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic and therapeutic yield of push-and-pull enteroscopy for symptomatic small bowel Crohn's disease strictures.
    Pohl J; May A; Nachbar L; Ell C
    Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):529-34. PubMed ID: 17556897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy.
    Matsumoto T; Iida M; Kohgo Y; Imamura A; Kusugami K; Nakano H; Fujiyama Y; Matsu T; Hibi T
    Scand J Gastroenterol; 2005 Dec; 40(12):1423-30. PubMed ID: 16316890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
    Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.
    Markowitz J; Hyams J; Mack D; Leleiko N; Evans J; Kugathasan S; Pfefferkorn M; Mezoff A; Rosh J; Tolia V; Otley A; Griffiths A; Moyer MS; Oliva-Hemker M; Wyllie R; Rothbaum R; Bousvaros A; Del Rosario JF; Hale S; Lerer T;
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1124-9. PubMed ID: 16861053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local injection of infliximab in the postoperative recurrence of Crohn's disease.
    Biancone L; Cretella M; Tosti C; Palmieri G; Petruzziello C; Geremia A; Calabrese E; Pallone F
    Gastrointest Endosc; 2006 Mar; 63(3):486-92. PubMed ID: 16500402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
    Kopylov U; Mantzaris GJ; Katsanos KH; Reenaers C; Ellul P; Rahier JF; Israeli E; Lakatos PL; Fiorino G; Cesarini M; Tsianos EV; Louis E; Ben-Horin S
    Aliment Pharmacol Ther; 2011 Feb; 33(3):349-57. PubMed ID: 21118397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with Crohn's disease.
    Ono Y; Hirai F; Matsui T; Beppu T; Yano Y; Takatsu N; Takaki Y; Nagahama T; Hisabe T; Yao K; Higashi D; Futami K
    Dig Endosc; 2012 Nov; 24(6):432-8. PubMed ID: 23078435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
    Baldassano R; Braegger CP; Escher JC; DeWoody K; Hendricks DF; Keenan GF; Winter HS
    Am J Gastroenterol; 2003 Apr; 98(4):833-8. PubMed ID: 12738464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M; Mary JY; Duclos B; Veyrac M; Dupas JL; Delchier JC; Laharie D; Moreau J; Cadiot G; Picon L; Bourreille A; Sobahni I; Colombel JF;
    Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
    Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab in Hispanics: characterization of response to infliximab in an ethnic minority with Crohn's disease.
    Sánchez JM; Maldonado JC; Torres EA; Rivera C
    P R Health Sci J; 2005 Mar; 24(1):11-7. PubMed ID: 15895872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.